US · TAK · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Takeda Pharmaceutical Company Limited (TAK) intrinsic value and stock valuation
$21.77as of 2026-11-21 · Mkt cap 53.21B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Takeda Pharmaceutical Company Limited DCF and intrinsic value
InvestorsCraft values TAK with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from TAK’s statements →
Takeda Pharmaceutical Company Limited Graham Number
Graham Number: $1,897.34d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cardinal Health, Inc. (CAH) $272.81
- Edwards Lifesciences Corporation (EW) $101.85
- Becton, Dickinson and Company (BDX) $212.78
- Haleon plc (HLN) $9.07
- Agilent Technologies, Inc. (A) $170.38
- IQVIA Holdings Inc. (IQV) $245.82
- Veeva Systems Inc. (VEEV) $266.22
- Alcon Inc. (ALC) $74.31
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $4.78T | $4.58T | $4.26T | $4.03T | $3.57T |
| Operating income | $573B | $342.6B | $214.1B | $490.5B | $460.8B |
| Net income | $203.3B | $107.9B | $144.1B | $317B | $230.1B |
| EPSd | $63.4M | $33.6M | $45.6M | $101M | $72.9M |
| Operating cash flow | $1.04T | $1.06T | $716.3B | $977.2B | $1.12T |
| Capital expenditure | -$-414.66B | -$-379.63B | -$-480.73B | -$-633.69B | -$-186.04B |
| Free cash flow | $626.8B | $677.6B | $235.6B | $343.5B | $937.1B |
| Total assets | $15.5T | $14.2T | $15.1T | $14T | $13.2T |
| Total debt | $4.9T | $4.52T | $4.84T | $4.38T | $4.35T |
| Net debt | $4.31T | $4.13T | $4.39T | $3.85T | $3.5T |
| Total equity | $7.81T | $6.94T | $7.27T | $6.35T | $5.68T |
| Cash and short-term investments | $597.6B | $405.6B | $472.9B | $553.7B | $875B |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $4.78T | $4.58T | $4.26T | $4.03T | $3.57T |
| Cost of revenue | $2.34T | $1.58T | $1.43T | $1.24T | $1.11T |
| Gross profit | $2.44T | $3T | $2.83T | $2.78T | $2.46T |
| Research and development expenses | $716.7B | $730.2B | $729.9B | $633.3B | $526.1B |
| Selling, general and administrative expenses | $1.15T | $1.1T | $1.05T | $997.3B | $886.4B |
| Other expenses | $0.00 | $823.8B | $834.4B | $662.3B | $588.9B |
| Operating expenses | $1.87T | $2.66T | $2.62T | $2.29T | $2T |
| Cost and expenses | $4.2T | $4.24T | $4.05T | $3.54T | $3.11T |
| Interest income | $223.9B | $19.6B | $78.1M | $5.51B | $4.59B |
| Interest expense | $379.1B | $137.3B | $1.06B | $117B | $122.4B |
| Depreciation and amortization | $764.6B | $761.4B | $644.5B | $664.4B | $583.2B |
| Ebitda | $1.42T | $1.21T | $1.14T | $1.28T | $1.18T |
| Operating income | $573B | $342.6B | $214.1B | $490.5B | $460.8B |
| Total other income/expenses, net | -$-297.16B | -$-167.5B | -$-161.28B | -$-115.42B | -$-158.27B |
| Income before tax | $275.9B | $175.1B | $52.8B | $375.1B | $302.6B |
| Income tax expense | $72.3B | $66.9B | -$-91.41B | $58.1B | $72.4B |
| Net income | $203.3B | $107.9B | $144.1B | $317B | $230.1B |
| Weighted average shares outstanding | $3.15B | $3.21B | $3.13B | $3.1B | $3.13B |
| Weighted average diluted shares outstanding | $3.21B | $3.21B | $3.16B | $3.14B | $3.15B |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $597.6B | $405.6B | $472.9B | $553.7B | $875B |
| Net receivables | $880.1B | $725.3B | $697.6B | $681.7B | $724.4B |
| Inventory | $1.4T | $1.22T | $1.21T | $986.5B | $853.2B |
| Total current assets | $3.1T | $2.52T | $2.56T | $2.4T | $2.59T |
| Property, plant and equipment, net | $2.13T | $1.97T | $1.99T | $1.69T | $1.58T |
| Goodwill and intangible assets | $9.27T | $8.96T | $9.68T | $9.06T | $8.23T |
| Long-term investments | $450.7B | $361.9B | $430.6B | $378.9B | $330.1B |
| Total non-current assets | $12.4T | $11.7T | $12.6T | $11.6T | $10.6T |
| Total assets | $15.5T | $14.2T | $15.1T | $14T | $13.2T |
| Accounts payable | $493.5B | $308.5B | $320B | $307.5B | $295.9B |
| Short-term debt | $514.4B | $548.9B | $367.3B | $339.6B | $204B |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $2.44T | $2.51T | $2.31T | $2.48T | $2.15T |
| Long-term debt | $4.39T | $3.97T | $4.48T | $4.04T | $4.14T |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $5.27T | $4.81T | $5.52T | $5.12T | $5.35T |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $7.71T | $7.31T | $7.83T | $7.6T | $7.49T |
| Common stock | $1.7T | $1.69T | $1.68T | $1.68T | $1.68T |
| Retained earnings | $1.06T | $1.19T | $1.39T | $1.54T | $1.48T |
| Accumulated other comprehensive income (loss) | $3.31T | $2.35T | $2.51T | $1.51T | $934.2B |
| Total equity | $7.81T | $6.94T | $7.27T | $6.35T | $5.68T |
| Total investments | $450.7B | $382.4B | $445.7B | $399B | $355.4B |
| Total debt | $4.9T | $4.52T | $4.84T | $4.38T | $4.35T |
| Net debt | $4.31T | $4.13T | $4.39T | $3.85T | $3.5T |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | -$-152.13B | $108.1B | $144.2B | $317B | $230.2B |
| Depreciation and amortization | $721.1B | $761.4B | $728B | $664.4B | $583.2B |
| Stock-based compensation | $72.8B | $72.9B | $70.9B | $60.7B | $43.4B |
| Change in working capital | $199.9B | -$-59.37B | -$-256B | -$-25.26B | $98.6B |
| Accounts receivable | -$-70.17B | -$-58.96B | $15.1B | $75.1B | $127.3B |
| Inventory | -$-61.29B | -$-34.97B | -$-115.74B | -$-79.16B | -$-46.15B |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $1.04T | $1.06T | $716.3B | $977.2B | $1.12T |
| Investments in property, plant and equipment | -$-176B | -$-200.8B | -$-175.42B | -$-140.66B | -$-123.25B |
| Acquisitions, net | $33.6B | $77.2B | $20B | $7.96B | -$-21.48B |
| Net cash used for investing activities | -$-369.14B | -$-367.06B | -$-463.86B | -$-607.1B | -$-198.13B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-51.6B | -$-51.86B | -$-2.33B | -$-26.93B | -$-77.53B |
| Dividends paid | -$-311.9B | -$-302.5B | -$-287.19B | -$-279.42B | -$-283.67B |
| Net cash used for financing activities | -$-496.82B | -$-751.43B | -$-354.42B | -$-709.15B | -$-1.07T |
| Net change in cash | $209.9B | -$-72.69B | -$-75.73B | -$-316.17B | -$-116.53B |
| Cash at end of period | $595.1B | $385.1B | $457.8B | $533.5B | $849.7B |
| Operating cash flow | $1.04T | $1.06T | $716.3B | $977.2B | $1.12T |
| Capital expenditure | -$-414.66B | -$-379.63B | -$-480.73B | -$-633.69B | -$-186.04B |
| Free cash flow | $626.8B | $677.6B | $235.6B | $343.5B | $937.1B |
Line items
Line items
Line items
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
- CEO
- Julie So-Young Kim
- Employees
- 47.03K
- Beta
- 0.09
Explore
Frequently asked questions
What is the intrinsic value of Takeda Pharmaceutical Company Limited (TAK)?
Takeda Pharmaceutical Company Limited (TAK) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TAK undervalued?
TAK trades at a price of $21.77 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.